FTSE MIB
35.398,82 -11,31 (-0,03%) Dow Jones
40.003,59 +134,21 (+0,34%) Nasdaq
16.685,97 -12,35 (-0,07%) Nikkei 225
38.787,38 -132,88 (-0,34%) Petrolio
80,00 +0,77 (+0,97%) Bitcoin EUR
61.431,12 +1.514,14 (+2,53%)
Atossa Therapeutics, Inc. (ATOS)
Dopo ore:
| Chiusura precedente | 1,6100 |
| Aperto | 1,6000 |
| Denaro | 1,5500 x 600 |
| Lettera | 1,6100 x 500 |
| Min-Max giorno | 1,5500 - 1,6000 |
| Intervallo di 52 settimane | 0,6200 - 2,3100 |
| Volume | |
| Media Volume | 1.924.572 |
| Capitalizzazione | 197,438M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,2400 |
| Prossima data utili | 12 ago 2024 - 16 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,33 |
GlobeNewswireAtossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023
SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023. Details of the company's participation are as follows: Cantor Fitzgerald Global Healthcare Conference 2023Format: Fireside Chat with
- GlobeNewswire
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Achieved significant enrollment milestones in three ongoing Phase 2 clinical trialsBroadened patent protection for proprietary (Z)-endoxifenStrengthened management team with appointment of Greg Weaver as Chief Financial OfficerEnded second quarter 2023 with $99.4 million of cash and cash equivalents SEATTLE, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unme
- GlobeNewswire
Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023
SEATTLE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines to address significant unmet needs in cancer, today announced that it will provide a business update and report financial results for the second quarter 2023 on Monday, August 14, 2023. Company management will host a conference call to review the results at 9:00 a.m. ET / 6:00 a.m. PT on August 14, 2023. Second Quarter 2023 Conference Cal
